Biogen shareholders elect biotech exec Susan Langer to the board after romantic partner departs
Biogen shareholders have elected Susan Langer to the drugmaker’s board, part of a series of changes to refresh the biotech’s governance.
Langer’s nomination to the board was controversial. After she was nominated earlier this month, Endpoints News reported that she was said to be in a personal relationship with departing board director and Sarissa Capital Management leader Alex Denner. Denner, a protégé of activist investor Carl Icahn, had been on Biogen’s board for more than a decade.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
